Drugs / wIPV
last change Dec 2018 re-read 3 minutes ago

wIPV

Developed for
poliomyelitis
Investigated by
Sinovac Biotech Co., Ltd

Trials 1

20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT03822767 Jun → Sep 2018 poliomyelitis Sinovac Biotech Co., Ltd Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as wIPV ClinicalTrials.gov intervention name — accepted as the source's own label NCT03822767 ↗
Route Intramuscular “Two intramuscular injections of the control vaccine(0.5 ml) on Day 0 and Day 30 respectively” NCT03822767 ↗